GlassScriptPhysician profile
Lynn R Sheppard
NPI 1134521115
$10,842.35
in general payments reported to CMS, 2019-2025
29 companies · $2,255 in 2025
The $2,255 reported for 2025 was more than what 95% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,002 · 2022: $2,957 · 2023: $1,269 · 2024: $2,360 · 2025: $2,255.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,595 · Travel and Lodging: $269 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,594.82 |
| Travel and Lodging | $268.96 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,191.58 | 2021-2025 | Jardiance |
| Abbott Laboratories | $1,272.74 | 2021-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Astrazeneca Pharmaceuticals LP | $988.41 | 2021-2025 | Farxiga, Wainua, Lokelma |
| E.R. Squibb & Sons, L.L.C. | $684.40 | 2021-2025 | Camzyos, Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $668.36 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $589.91 | 2021-2023 | Xarelto |
| Scpharmaceuticals INC. | $568.48 | 2024-2025 | |
| Amgen INC. | $493.80 | 2021-2023 | Repatha, Tavneos |
| Merck Sharp & Dohme LLC | $484.43 | 2021-2025 | Verquvo, Capvaxive |
| Alnylam Pharmaceuticals INC. | $443.46 | 2022-2025 | Onpattro |
| Cvrx, INC. | $417.42 | 2025 | Barostim Neo System |
| Boston Scientific Corporation | $384.60 | 2021-2022 | |
| Pfizer INC. | $309.87 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $213.64 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $181.94 | 2021-2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $156.98 | 2023-2024 | Veltassa |
| Lexicon Pharmaceuticals, INC. | $140.35 | 2024 | Inpefa |
| Bridgebio Pharma, INC. | $126.38 | 2025 | Attruby |
| Actelion Pharmaceuticals US, INC. | $95.63 | 2024 | Opsumit, Uptravi |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $92.62 | 2024-2025 | Lifevest |
| Kiniksa Pharmaceuticals, LTD. | $79.67 | 2021-2023 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $53.06 | 2022-2023 | |
| Kestra Medical Technology Services, INC. | $52.28 | 2025 | Assure Wcd |
| Abiomed | $48.69 | 2024 | Impella |
| Otsuka America Pharmaceutical, INC. | $25.69 | 2023 | Jynarque |
| Travere Therapeutics, INC. | $24.75 | 2023 | |
| Amarin Pharma, INC. | $23.81 | 2022 | |
| Elutia, INC. | $15.10 | 2023 | |
| Edwards Lifesciences Corporation | $14.30 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lynn Sheppard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.